Meridiem Capital Partners’s RxSight RXST Stock Holding History

Meridiem Capital Partners’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-174,014	Closed	-$1.56M	–	98
2025 Q3	$1.56M	Buy	+174,014	New	+$1.53M	0.1%	65

Other funds holding RXST

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Meridiem Capital Partners's RXST Position: Q4 2025 in Review

Meridiem Capital Partners sold out of RxSight (RXST) in Q4 2025, closing a stake of 174,014 shares — an estimated $1.56M sold.

Meridiem Capital Partners first reported a position in RXST in Q3 2025 and held it in 1 quarter. The position peaked at $1.56M in Q3 2025. 163 funds tracked by Wall St. Rank hold RXST as of Q4 2025.

Meridiem Capital Partners reported no remaining RxSight position as of Q4 2025 after selling out during the quarter.
Meridiem Capital Partners sold 174,014 RxSight shares in Q4 2025, an estimated $1.56M.
Meridiem Capital Partners first reported a position in RxSight in Q3 2025 and held it in 1 quarter.
Meridiem Capital Partners's RxSight position peaked at $1.56M in Q3 2025.
163 funds tracked by Wall St. Rank held RxSight as of Q4 2025.

Based on Meridiem Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.